Best Selling Pharma Products

Prepared By:Mrinal Patil (P-011)

Alay Joshi (P-008)Rohit Patel (Q-003)

GLOBAL PHARMA MARKET SCENARIO

• Global Pharmaceutical Market Report & Forecast: 2012-2017” : The global pharmaceutical market is expected to grow at a CAGR of 5% during 2011-2017 exceeding sales worth US$ 1.1 Trillion by 2017.

• The research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market during the forecast period, indicating large opportunities for generics manufacturers .

• Spending on medicines which was estimated at $856 billion in 2010, is expected to reach nearly $1,100 billion in 2015, reflecting a slowing growth rate of 36 % over the five year period compared to 6.2 per cent annual growth over the past five years2

Top 10 Global Pharma Products

Products Rank Growth Rate(%)

Humira 1 22.1

Lantus 2 30.4

Sovaldi 3 98.64

Abilify 4 19.2

Enbrel 5 11.0

Seretide 6 -5.3

Crestor 7 5.6

Remicade 8 7.7

Nexium 9 -1.4

Mabthera 10 4.3

HUMIRA• Humira is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic

arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa.

• It is also used to treatCrohn's disease or ulcerative colitis

Lantus

8014

10331

0

2000

4000

6000

8000

10000

12000

2013 2014

Sales (US $million)

SOVALDI

• Sovaldi is an antiviral medication that prevents hepatitis C virus (HCV) cells from multiplying in the body.

70

9375

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

10000

2013 2014

Sales (US $million)

Abilify

• Abilify is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). It is also used together with other medications to treat major depressive disorder in adults

ENBREL

Enbrel is used to treat the symptoms of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, and

to prevent joint damage caused by these conditions

Seretide

7705

89079,198

8,652

6500

7000

7500

8000

8500

9000

9500

2011 2012 2013 2014

Revenues in US million Dollars

It is used to treatment of asthma and chronic obstructive pulmonary disease (COPD).

CRESTOR

81368215

8,140

8,473

7900

8000

8100

8200

8300

8400

8500

2011 2012 2013 2014

Revenues in US million Dollars

It is used to treat high cholesterol and related conditions, and to prevent cardiovascular disease.

Crestor is the fourth-highest selling drug in the United States, accounting for approx. $5.2 billion in sales in 2013.

REMICADE

7259

7678

7000

7100

7200

7300

7400

7500

7600

7700

7800

2012 2013

Remicade Sales

Sales ( US $ million)

Remicade is used to treat rheumatoid arthritis. It is also used to treat Crohn'sdisease or ulcerative colitis.

Patent holder- Johnson & Johnson

• In the United States, remicade can cost $19,000 to $22,000 a year per patient.

• Johnson & Johnson reported in its 2013 annual report, "REMICADE® (infliximab), accounted for approximately 9.4% of the Company's total revenues for fiscal 2013.

NexiumNexium (esomeprazole) is a proton pump inhibitor that decreases the amount of acid produced in the stomach.Nexium is used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions involving excessive stomach acid such as Zollinger-Ellison syndrome. It is also used to promote healing of erosive esophagitis

72247407

7,8677,681

6800

7000

7200

7400

7600

7800

8000

2011 2012 2013 2014

MABTHERA

It consist of Rituximab which is an anticancer drug molecule

MABTHERA is used to treat non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia.

5950

6263

5750

5800

5850

5900

5950

6000

6050

6100

6150

6200

6250

6300

2012 2013

MabThera sales in 2013

Sales (US $ million)

54295950

6,363 6,552

0

1000

2000

3000

4000

5000

6000

7000

2011 2012 2013 2014

Mabthera

Indian Therapeutic Segments

Top 20 Global Therapeutic Categories

PHARMACEUTICAL COMPANIES

Global Generic market

Sales

North America

Europe

Brazil

China

India

Russia

North america : 32%

Europe : 23%

Brazil : 5%

China : 13%

India : 4%

Russia : 2%

Estimates

• According to IMS Health, spending on medicines will reach nearly $1,100 billion in 2015 with a growth rate of 3-6 percent over the last five-year period.

• The overall outlook of the global pharma industry in 2015 and beyond is expected to be as follows:

• A dozen products launched in 2015 are forecast to achieve blockbuster sales by 2020

• Drugs treating high cholesterol and heart failure will dominate the field with a combined 2020 sales forecast of US$8 billion

• Sovaldi and its combination product Harvoni will take the number one worldwide seller spot with forecasted sales of $15.3 billion in 2015

•

REFERENCES

• http://www.businessweek.com/investor/content/may2009/pi2009051_087752.htm

• http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers

• http://www.statista.com/statistics/318206/revenue-of-humira

• www.drugs.com/